Sambati V, Laudisio S, Motta M, Esposito S
Int J Mol Sci. 2024; 25(20).
PMID: 39456788
PMC: 11508002.
DOI: 10.3390/ijms252011006.
Shen G, Li W, Zhang Y, Chen L
BMC Pediatr. 2024; 24(1):230.
PMID: 38561707
PMC: 10985934.
DOI: 10.1186/s12887-024-04718-x.
Shintani T, Imamura C, Ueyama-Toba Y, Inui J, Watanabe A, Mizuguchi H
Mol Ther Methods Clin Dev. 2023; 30:429-442.
PMID: 37663646
PMC: 10471830.
DOI: 10.1016/j.omtm.2023.08.003.
Bai J, Li L, Liu H, Liu S, Bai L, Song W
J Clin Transl Hepatol. 2021; 9(2):180-186.
PMID: 34007799
PMC: 8111108.
DOI: 10.14218/JCTH.2020.00108.
Naji-Talakar S, Sharma S, Martin L, Barnhart D, Prasad B
Expert Opin Drug Metab Toxicol. 2020; 17(3):273-289.
PMID: 33256492
PMC: 8346204.
DOI: 10.1080/17425255.2021.1858051.
Combined Effects of Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia.
Bai J, Luo L, Liu S, Liang C, Bai L, Chen Y
Front Genet. 2019; 10:1073.
PMID: 31737051
PMC: 6834774.
DOI: 10.3389/fgene.2019.01073.
North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma.
McWilliams R, Foster N, Mahoney M, Smyrk T, Murray J, Ames M
Cancer. 2017; 123(18):3494-3501.
PMID: 28493308
PMC: 5589489.
DOI: 10.1002/cncr.30766.
Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPARα.
Hinds Jr T, Hosick P, Chen S, Tukey R, Hankins M, Nestor-Kalinoski A
Am J Physiol Endocrinol Metab. 2017; 312(4):E244-E252.
PMID: 28096081
PMC: 5406988.
DOI: 10.1152/ajpendo.00396.2016.
Does bilirubin prevent hepatic steatosis through activation of the PPARα nuclear receptor?.
Hinds Jr T, Adeosun S, Alamodi A, Stec D
Med Hypotheses. 2016; 95:54-57.
PMID: 27692168
PMC: 5433619.
DOI: 10.1016/j.mehy.2016.08.013.
Acute cholangitis in an old patient with Crigler-Najjar syndrome type II - a case report.
Fernandes S, Miguel Moura C, Rodrigues B, Araujo Correia L, Cortez-Pinto H, Velosa J
BMC Gastroenterol. 2016; 16:33.
PMID: 26968162
PMC: 4788912.
DOI: 10.1186/s12876-016-0449-9.
Inherited disorders of bilirubin clearance.
Memon N, Weinberger B, Hegyi T, Aleksunes L
Pediatr Res. 2015; 79(3):378-86.
PMID: 26595536
PMC: 4821713.
DOI: 10.1038/pr.2015.247.
Association of Neonatal Hyperbilirubinemia with UGT1A1 Gene Polymorphisms: A Meta-Analysis.
Yu Z, Zhu K, Wang L, Liu Y, Sun J
Med Sci Monit. 2015; 21:3104-14.
PMID: 26467199
PMC: 4612146.
DOI: 10.12659/msm.894043.
Alterations in the cell cycle in the cerebellum of hyperbilirubinemic Gunn rat: a possible link with apoptosis?.
Robert M, Furlan G, Rosso N, Gambaro S, Apitsionak F, Vianello E
PLoS One. 2013; 8(11):e79073.
PMID: 24223883
PMC: 3815147.
DOI: 10.1371/journal.pone.0079073.
The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.
AlFadhli S, Al-Jafer H, Hadi M, Al-Mutairi M, Nizam R
PLoS One. 2013; 8(10):e77681.
PMID: 24204915
PMC: 3813713.
DOI: 10.1371/journal.pone.0077681.
Metabolism and disposition of acetaminophen: recent advances in relation to hepatotoxicity and diagnosis.
McGill M, Jaeschke H
Pharm Res. 2013; 30(9):2174-87.
PMID: 23462933
PMC: 3709007.
DOI: 10.1007/s11095-013-1007-6.
Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease.
Lingenhel A, Kollerits B, Schwaiger J, Hunt S, Gress R, Hopkins P
Exp Gerontol. 2008; 43(12):1102-7.
PMID: 18790042
PMC: 2648823.
DOI: 10.1016/j.exger.2008.08.047.
In vitro studies of intestinal permeability and hepatic and intestinal metabolism of 8-prenylnaringenin, a potent phytoestrogen from hops (Humulus lupulus L.).
Nikolic D, Li Y, Chadwick L, van Breemen R
Pharm Res. 2006; 23(5):864-72.
PMID: 16715376
PMC: 1764547.
DOI: 10.1007/s11095-006-9902-8.
Gilbert's syndrome: High frequency of the (TA)7 TAA allele in India and its interaction with a novel CAT insertion in promoter of the gene for bilirubin UDP-glucuronosyltransferase 1 gene.
Farheen S, Sengupta S, Santra A, Pal S, Dhali G, Chakravorty M
World J Gastroenterol. 2006; 12(14):2269-75.
PMID: 16610035
PMC: 4087660.
DOI: 10.3748/wjg.v12.i14.2269.
Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.
Alcorn J, McNamara P
Clin Pharmacokinet. 2002; 41(12):959-98.
PMID: 12222995
DOI: 10.2165/00003088-200241120-00003.
Bile bilirubin pigment analysis in disorders of bilirubin metabolism in early infancy.
Lee W, McKiernan P, Beath S, Preece M, Baty D, Kelly D
Arch Dis Child. 2001; 85(1):38-42.
PMID: 11420196
PMC: 1718838.
DOI: 10.1136/adc.85.1.38.